Drug intelligence / Profile preview

PGUS-OA1

Development stage: Preclinical
Lead developer: PrimeGen Biotech
Modality: Stem Cell Therapies → Cell Therapies

Overview

PGUS-OA1 is a preclinical-stage therapeutic candidate being developed by PrimeGen Biotech for the treatment of osteoarthritis. PrimeGen Biotech is a regenerative medicine company that focuses on the development of stem cell-based therapies, specifically utilizing their proprietary Germline Pluripotent Stem Cell (GPSC) platform. PGUS-OA1 is designed to address the degenerative nature of osteoarthritis, likely by promoting cartilage repair and modulating the inflammatory environment within the joint to restore function and provide long-term relief.

Beyond the preview

Go deeper on PGUS-OA1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PGUS-OA1.

Explore the full profile